Mesalazine Changes Apoptosis and Proliferation in Normal Mucosa of Patients with Sporadic Polyps of the Large Bowel

 

 Buy Article Permissions and Reprints

Background and Study Aims: Regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the occurrence of colorectal adenoma and carcinoma, possibly by inducing apoptosis and/or decreasing proliferation in colorectal epithelial cells. Mesalazine is widely used in the treatment of patients with inflammatory bowel disease, and well tolerated. We investigated its effect on apoptosis and proliferation of colorectal mucosa in 21 patients with sporadic polyps of the large bowel.

Patients and Methods: In total, 17 patients with sporadic colorectal polyps (≥ 5 mm) underwent polypectomy and biopsy of uninvolved mucosa before and after treatment with 1 g/d mesalazine for 1, 3, 7 or 14 days. Four additional patients served as untreated controls. Apoptotic index (AI) was measured by terminal deoxynucleotidyl transferase-mediated d-uridine triphosphate nick-end labeling (TUNEL) assay; proliferation index (PI) was measured by immunohistochemical examination with anti-Ki67 antibody.

Results: Al was significantly increased 1 and 3 days after initiation of treatment with mesalazine compared with controls (P = 0.0107 for the 1-day treatment group and P = 0.0142 for the 3-day treatment group), and seemed to remain largely unchanged after longer treatment duration. Proliferation appeared to be decreased by mesalazine in all treatment groups, while proliferation in controls did not change (P = 0.0107 for the 1-day treatment group and P = 0.0142 for the 3-day treatment group compared with controls.

Conclusions: Mesalazine significantly induces apoptosis and decreases proliferation in colorectal mucosa in patients with sporadic polyps of the large bowel. This may be clinically relevant in that it may lower the rate of polyp recurrence after polypectomy, thereby possibly contributing to the chemoprevention of sporadic colorectal carcinoma.

References

• 1 Parker S L, Tong T, Bolden S, Wingo P A. Cancer Statistics, 1996.  CA Cancer J Clin. 1996;  46 5-27
  PubMedGoogle Scholar
• 2 Kune G, Kune S, Watson L. Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne Colorectal Cancer Study.  Cancer Res. 1988;  48 4399-4404
  PubMedGoogle Scholar
• 3 Thun M J, Namboodiri M M, Heath C W . Aspirin use and reduced risk of fatal colon cancer.  N Engl J Med. 1991;  325 1593-1596
  CrossrefPubMedGoogle Scholar
• 4 Giovannucci E, Egan K M, Hunter D J, et al. Aspirin and the risk of colorectal cancer in women.  N Engl J Med. 1995;  333 609-614
  CrossrefPubMedGoogle Scholar
• 5 Smalley W, Ray W A, Daugherty J, Griffin M R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study.  Arch Intern Med. 1999;  159 161-166
  CrossrefPubMedGoogle Scholar
• 6 Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma.  Cancer. 1998;  82 2326-2333
  CrossrefPubMedGoogle Scholar
• 7 Jacoby R F, Marshall D J, Newton M A, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam.  Cancer Res. 1996;  56 710-714
  PubMedGoogle Scholar
• 8 Rao C V, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.  Cancer Res. 1995;  55 1464-1472
  PubMedGoogle Scholar
• 9 Ritland S R, Gendler S J. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.  Carcinogenesis. 1999;  20 51-58
  CrossrefPubMedGoogle Scholar
• 10 Mahmoud N N, Dannenberg A J, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis.  Surgery. 1998;  124 225-231
  CrossrefPubMedGoogle Scholar
• 11 Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis.  Gastroenterology. 1991;  101 635-639
  PubMedGoogle Scholar
• 12 Giardello F M, Hamilton S R, Krush A J, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.  N Engl J Med. 1993;  328 1313-1316
  CrossrefPubMedGoogle Scholar
• 13 Matsuhashi N, Nakajima A, Fukushima Y, et al. Effects of sulindac on sporadic colorectal adenomatous polyps.  Gut. 1997;  40 344-349
  PubMedGoogle Scholar
• 14 Wallace J L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.  Gastroenterology. 1997;  112 1000-1016
  PubMedGoogle Scholar
• 15 Henry D, Lim L L, Garcia Rodriguez L A, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis.  BMJ. 1996;  312 1563-1566
  CrossrefPubMedGoogle Scholar
• 16 Bjarnasson I, Hayllar J, MacPherson A J, Russell A S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.  Gastroenterology. 1993;  104 1832-1847
  CrossrefPubMedGoogle Scholar
• 17 Shmueli E, Record C O. Adverse effects of the aminosalicylates.  Adverse Drug Reaction Bulletin. 1994;  165 623-626
  PubMedGoogle Scholar
• 18 Brimblecombe R. Mesalazine. A global safety evaluation.  Scand J Gastroenterol. 1990;  25 (Suppl. 172) 66-68
  PubMedGoogle Scholar
• 19 Allgayer H, Ahnfelt N O, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease.  Gastroenterology. 1989;  97 38-41
  PubMedGoogle Scholar
• 20 Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107 117-120
  CrossrefPubMedGoogle Scholar
• 21 Moody G A, Jayanthi V, Probert C SJ, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.  Eur J Gastroenterol Hepatol. 1996;  8 1179-1183
  CrossrefPubMedGoogle Scholar
• 22 Eaden J A, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study.  Gastroenterology. 1999;  116 (Suppl.) 1739
  PubMedGoogle Scholar
• 23 MacGregor D J, Kim Y S, Siddiki B B, et al. Induction of colon cancer cell apoptosis in vitro and inhibition of intestinal tumor formation in Min/+mice by balsalazide and metabolites.  Gastroenterology. 1996;  110 (Suppl.) 553
  PubMedGoogle Scholar
• 24 Bus P J, Nagtegaal I D, Verspaget H W, et al. Topical administration of 5-ASA results in increased apoptosis of colorectal cancer.  Gastroenterology. 1999;  116 (Suppl.) 1680
  PubMedGoogle Scholar
• 25 MacGregor D J, Kim Y S, Sleisenger M E, Johnson L K. Inhibition of colon cancer cell proliferation in vitro and azoxymethane-induced aberrant crypt formation in vivo by balsalazide and metabolites.  Gastroenterology. 1995;  108 (Suppl.) 500
  PubMedGoogle Scholar
• 26 Marnett L J. Aspirin and the potential role of prostaglandins in colon cancer.  Cancer Res. 1992;  52 5575-5589
  PubMedGoogle Scholar
• 27 Smith B J, Curtis J F, Eling T E. Bioactivation of xenobiotics by prostaglandin H synthetase.  Chem Biol Interact. 1991;  79 245-264
  PubMedGoogle Scholar
• 28 Tsujii M, Kawano S, Tsujii S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells.  Cell. 1998;  93 705-716
  CrossrefPubMedGoogle Scholar
• 29 Sano H, Kawahito Y, Wilder R L, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer.  Cancer Res. 1995;  55 3785-3789
  PubMedGoogle Scholar
• 30 Eberhart C E, Coffey R J, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.  Gastroenterology. 1994;  107 1183-1188
  PubMedGoogle Scholar
• 31 Partik G, Kahl-Rainer P, Sedivy R, et al. Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression.  Virchows Arch. 1998;  432 415-426
  CrossrefPubMedGoogle Scholar
• 32 Tsujitani S, Shirai H, Tatebe S, et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma.  Cancer. 1996;  77 1711-1716
  PubMedGoogle Scholar
• 33 Bedi A, Pasricha P J, Akhtar A J, et al. Inhibition of apoptosis during development of colorectal cancer.  Cancer Res. 1995;  55 1811-1816
  PubMedGoogle Scholar
• 34 Moss S F, Scholes J V, Holt P R. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling.  Dig Dis Sci. 1996;  41 2238-2247
  PubMedGoogle Scholar
• 35 Langman M, Boyle P. Chemoprevention of colorectal cancer.  Gut. 1998;  43 578-585
  PubMedGoogle Scholar
• 36 Qiao L, Hanif R, Sphicas E, et al. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells.  Biochem Pharmacol. 1998;  55 53-64
  CrossrefPubMedGoogle Scholar
• 37 Piazza G A, Rahm A LK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.  Cancer Res. 1995;  55 3110-3116
  PubMedGoogle Scholar
• 38 Elder D JE, Hague A, Hicks D J, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines.  Cancer Res. 1996;  56 2273-2276
  PubMedGoogle Scholar
• 39 Giardina C, Boulares H, Inan M S. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species.  Biochim Biophys Acta. 1999;  1448 425-438
  PubMedGoogle Scholar
• 40 Erickson B A, Longo W E, Panesar N, et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.  J Surg Res. 1999;  81 101-107
  CrossrefPubMedGoogle Scholar
• 41 Picariello L, Brandi M L, Formigli L, et al. Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms.  Eur J Pharmacol. 1998;  360 105-112
  CrossrefPubMedGoogle Scholar
• 42 Pasricha P J, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.  Gastroenterology. 1995;  109 994-998
  PubMedGoogle Scholar
• 43 Winde G, Schmid K W, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment.  Dis Colon Rectum. 1995;  38 813-830
  CrossrefPubMedGoogle Scholar
• 44 Eide T J. Risk of colorectal cancer in adenoma-bearing individuals within a defined population.  Int J Cancer. 1986;  38 173-176
  CrossrefPubMedGoogle Scholar
• 45 O'Brien M J, Winawer S J, Zauber A G, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas.  Gastroenterology. 1990;  98 371-379
  PubMedGoogle Scholar
• 46 Neugut A I, Jacobson J S, Ahsan H, et al. Incidence and recurrence rates of colorectal adenomas: a prospective study.  Gastroenterology. 1995;  108 402-408
  CrossrefPubMedGoogle Scholar
• 47 Van Stolk R U, Beck G J, Baron J A, et al, for the Polyp Prevention Study Group. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up.  Gastroenterology. 1998;  115 13-18
  PubMedGoogle Scholar
• 48 Gavrieli Y, Sherman Y, Ben-Sasson S A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.  J Cell Biol. 1992;  119 493-501
  CrossrefPubMedGoogle Scholar
• 49 Sträter J, Koretz K, Günthert A R, Möller P. In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis.  Gut. 1995;  37 819-825
  PubMedGoogle Scholar
• 50 Frisch S M, Francis H. Disruption of epithelial cell-matrix interaction induces apoptosis.  J Cell Biol. 1994;  124 619-626
  CrossrefPubMedGoogle Scholar
• 51 Liu L U, Holt P R, Krivosheyev V, Moss S F. Human right and left colon differ in epithelial cell apoptosis and in the expression of bak, a pro-apoptotic Bcl-2 homologue.  Gut. 1999;  45 45-50
  PubMedGoogle Scholar
• 52 Anti M, Iascone E, Morini S, et al. Apoptosis and cell proliferation along the entire colonic mucosa in subjects at risk for colorectal cancer.  Gastroenterology. 1997;  112 (Suppl.) 533
  PubMedGoogle Scholar
• 53 Spagnesi M T, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.  Gastroenterology. 1994;  106 362-366
  PubMedGoogle Scholar
• 54 Bostick R M, Fosdick L, Wood J R, et al. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial.  J Natl Cancer Inst. 1995;  87 1307-1315
  PubMedGoogle Scholar
• 55 Goldberg Y, Nassif I I, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alteration in tumor suppressor and cell cycle-regulatory proteins.  Oncogene. 1996;  12 893-901
  PubMedGoogle Scholar
• 56 Lee F D. Importance of apoptosis in the histopathology of drug related lesions of the large intestine.  J Clin Pathol. 1993;  46 118-122
  PubMedGoogle Scholar
• 57 Keller J J, Offerhaus G JA, Goodman S N, et al. Change in apoptosis in patients treated with sulindac.  Gastroenterology. 1998;  114 (Suppl.) 2550
  PubMedGoogle Scholar
• 58 Sandoval M, Liu X, Mannick E E, et al. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine.  Gastroenterology. 1997;  113 1480-1488
  PubMedGoogle Scholar
• 59 Shiff S J, Qioa L, Tsai L L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.  J Clin Invest. 1995;  96 491-503
  CrossrefPubMedGoogle Scholar
• 60 Yang F, de Villiers W JS, McClain C J, Varilek G W. Mesalamine modulates nuclear factor-kB/IkB-alpha in Caco-2 cells.  Gastroenterology. 1997;  112 (Suppl.) 1125
  PubMedGoogle Scholar
• 61 Kaiser G C, Yan F, Polk D B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.  Gastroenterology. 1999;  116 602-609
  CrossrefPubMedGoogle Scholar
• 62 Wahl C, Liptay S, Adler G, Schmid R M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappaB.  J Clin Invest. 1998;  101 1163-1174
  PubMedGoogle Scholar

M.D. W. H. Schmiegel

Dept. of Internal Medicine Medizinische Universitätsklinik Knappschaftskrankenhaus

In der Schornau 23 - 25

44892 Bochum

Germany

Phone: +49-234-299-3409

Email: wolff.schmiegel@ruhr-uni-bochum.de